FarmaKology Newsletter - Issue #34

30 Drugs Facing Patent Expirations and Generic Entry in 2020 - 2021

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

JUXTAPID 

Generic name: lomitapide mesylate

Patent Expiration / Generic Entry Opportunity February 21, 2020

Generic Entry Controlled by: Patent 5,712,279

JUXTAPID is a drug marketed by Aegerion. There are nine patents protecting this drug.

Learn more from here

APTIVUS 

Generic name: tipranavir

Patent Expiration / Generic Entry Opportunity April 29, 2020

Generic Entry Controlled by: Patent 5,852,195

APTIVUS is a drug marketed by Boehringer Ingelheim. There are three patents protecting this drug.

Learn more from here

FORTOVASE 

Generic name: saquinavir

Patent Expiration / Generic Entry Opportunity May 16, 2020

Generic Entry Controlled by: Patent 6,352,717

FORTOVASE is a drug marketed by Hoffmann La Roche. There is one patent protecting this drug.

Learn more from here

EGRIFTA 

Generic name: tesamorelin acetate

Patent Expiration / Generic Entry Opportunity May 26, 2020

Generic Entry Controlled by: Patent 5,861,379

EGRIFTA is a drug marketed by Theratechnologies. There are five patents protecting this drug.

Learn more from here

VYXEOS 

Generic name: cytarabine; daunorubicin

Patent Expiration / Generic Entry Opportunity August 03, 2020

Generic Entry Controlled by: FDA Regulatory Exclusivity

VYXEOS is a drug marketed by Celator Pharms. There are eight patents protecting this drug.

Learn more from here

CIPRODEX 

Generic name: ciprofloxacin; dexamethasone

Patent Expiration / Generic Entry Opportunity August 10, 2020

Generic Entry Controlled by: Patent 6,359,016

CIPRODEX is a drug marketed by Novartis. There are six patents protecting this drug and one Paragraph IV challenge.

Learn more from here

SOLAGE 

Generic name: mequinol; tretinoin

Patent Expiration / Generic Entry Opportunity August 24, 2020

Generic Entry Controlled by: Patent 5,194,247

SOLAGE is a drug marketed by Almirall. There is one patent protecting this drug.

Learn more from here

THALOMID 

Generic name: thalidomide

Patent Expiration / Generic Entry Opportunity October 23, 2020

Generic Entry Controlled by: Patent 6,315,720

THALOMID is a drug marketed by Celgene. There are nine patents protecting this drug and three Paragraph IV challenges.

Learn more from here

DULERA 

Generic name: formoterol fumarate; mometasone furoate

Patent Expiration / Generic Entry Opportunity December 20, 2020

Generic Entry Controlled by: FDA Regulatory Exclusivity

DULERA is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

Learn more from here

OVIDREL 

Generic name: choriogonadotropin alfa

Patent Expiration / Generic Entry Opportunity March 16, 2021

Generic Entry Controlled by: Patent 4,840,896

OVIDREL is a drug marketed by Emd Serono. There is one patent protecting this drug.

Learn more from here

DrugPatentWatch

DrugPatentWatch provides actionable business intelligence on small-molecule drugs

DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications.

Use cases for the DrugPatentWatch platform include:

• Branded pharmaceutical global business intelligence and forecasting

• Generic drug and API manufacturer portfolio management

• Wholesalers preventing overstock of off-patent drugs

• Healthcare payer formulary management and budget management

Different plans are available, focusing on general business intelligence, expired patents, and forecasting.